Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns
Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns
复制标题
DOI：
10.1191/1352458505ms1131oa
复制
发表时间：
2005-01-01
影响因子：
5.8
通讯作者：
Hutchinson, M
中科院分区：
文献类型：
--
作者：
O'Rourke, KET;Hutchinson, M
β-干扰素（IFNB）在复发缓解型多发性硬化（RRMS）和继发进展型MS（SPMS）中的停止率估计值各不相同，主要来自多中心研究。这是一项回顾性的，基于医院图表的研究，394例患者由一名神经科医生治疗长达8年。本研究的目的是确定在一个支持性良好的队列中IFNB停药的频率和时间，并调查开始IFNB时的临床疾病类型或停药原因是否影响停药率。中位随访时间为49个月. 5年内的总体IFNB停止率为28%; 3年随访后，RRMS（14%）和SPMS（23%）的IFNB停止率存在显著差异（P = 0.0003）。患者在中位13个月后因副作用而停止IFNB，在中位35个月后因治疗失败而停止IFNB（P = 0.0004）。SPMS组因治疗失败而停止IFNB的患者明显多于RRMS组（P = 0.037）。结论：IFNB停药发生在治疗过程中的早期，由于副作用。停止IFNB治疗在SPMS中更常见，并且更多是由于治疗失败而不是副作用。
Estimates of the beta- interferon ( IFNB) stopping rate in relapsing - remitting multiple sclerosis ( RRMS) and secondary progressive MS ( SPMS) vary and have been mainly derived from multicentre studies. This is a retrospective, hospital chart- based study of 394 patients treated by a single neurologist for up to eight years. The aims of the study were to ascertain the frequency and timing of IFNB discontinuation in a well supported cohort, and to investigate whether the clinical disease type at the initiation of IFNB or the reason for discontinuation influenced stopping rates. The median follow- up was 49 months. The overall IFNB stopping rate was 28% over five years; there was a significant difference between the IFNB stopping rates for RRMS ( 14%) and SPMS ( 23%) after three years of follow- up ( P = 0.0003). Patients stopped IFNB due to side effects after a median of 13 months, and due to failure of therapy after a median of 35 months ( P = 0.0004). Significantly more patients with SPMS than with RRMS stopped IFNB due to treatment failure ( P = 0.037). Conclusion: IFNB discontinuation occurred earlier in the treatment course when due to side effects. Stopping IFNB therapy was more common in SPMS and was more often due to treatment failure than side effects.